PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Dr Emma Morris

Research Summary

* Novel approaches for generation of antigen-specific T cells for leukaemia and cancer immunotherapy. * Retroviral gene transfer of T cell receptor (TCR) genes into T cells and haematopoietic stem cells to re-direct antigen-specificity. * The generation of MHC class I-restricted tumour antigen-specific CD4+ helper T cells to augment CD8+ T cell mediated tumour immunotherapy. * Analysis of functional avidity and signalling pathways of tumour antigen-specific TCRs. * Investigation of the role of the CD8 co-receptor in TCR transduced CD4+ helper T cells and conventional CD8+ T cells. * The generation of pre-clinical models for the evaluation of WT1-specific immunotherapy (WT1 is a tumour associated antigen over-expressed in myelodysplasia (MDS), leukaemias (AML, CML), breast, ovarian, prostate and colon cancers. * Isolation of TCRs from T cell clones specific for tumour antigens. * Generation of antigen-specific regulatory T cells using TCR gene transfer.

Research Activities

  • Gene and Cellular Therapy of Haematological Malignancies

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Dejardin O,Rachet B,Morris E,Bouvier V,Jooste V,Haynes R,Coombes EG,Forman D,Jones AP,Bouvier AM,Launoy G (2013) Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997-2004. Br J Cancer, 108(4), 775 - 783. 10.1038/bjc.2013.33.
  2. Xue SA,Gao L,Ahmadi M,Ghorashian S,Barros RD,Pospori C,Holler A,Wright G,Thomas S,Topp M,Morris EC,Stauss HJ (2013) Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology, 2(1), e22590. 10.4161/onci.22590.
  3. Townsend WM,Holroyd A,Pearce R,Mackinnon S,Naik P,Goldstone AH,Linch DC,Peggs KS,Thomson KJ,Singer M,Howell DC,Morris EC (2013) Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol, 161(4), 578 - 586. 10.1111/bjh.12294.
  4. Morris E,Gore M,Baker A,Thrasher AJ (2013) Moving forward on shifting sands: ethical regulation of gene therapy clinical trials in the United kingdom. Mol Ther, 21(4), 715 - 716. 10.1038/mt.2013.43.
  5. Nicholson EK,Ahmadi M,Holler A,Pike R,Carpenter B,Thomas S,Ghorashian S,Xue S-A,Stauss H,Morris E (2012) Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells BLOOD, 120(21).
  6. Nicholson EK,Ahmadi M,Holler A,Pike R,Carpenter B,Thomas S,Ghorashian S,Xue S-A,Stauss H,Morris E (2012) Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells BLOOD, 120(21).
  7. Nicholson E,Ahmadi M,Thomas S,Holler A,Carpenter B,Xue SA,Stauss H,Morris E (2012) Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells BRITISH JOURNAL OF HAEMATOLOGY, 157, 87 - 87.
  8. Loosemore M,Walsh SB,Morris E,Stewart G,Porter JB,Montgomery H (2012) Sudden exertional death in sickle cell trait. Br J Sports Med, 46(5), 312 - 314. 10.1136/bjsports-2011-090521.
  9. Mohamedbhai SG,Edwards N,Morris EC,Mackinnon S,Thomson KJ,Peggs KS (2012) Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br J Haematol, 156(4), 516 - 522. 10.1111/j.1365-2141.2011.08944.x.
  10. Thomson KJ,Kottaridis P,Cassoni A,Morris EC,Khwaja A,Linch DC,Chakraverty R,Peggs KS,Mackinnon S (2012) ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZUMAB-DEPLETED GRAFTS BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), S339 - S340.
  11. Chua I,Xue SA,Holler A,Maniusyte R,Zamoyska R,Stauss HJ,Morris EC (2012) Exploiting CD8 beta mutations which increase TCR avidity to improve the function of genetically modified T cells for immunotherapy BRITISH JOURNAL OF HAEMATOLOGY, 157, 87 - 87.
  12. Uttenthal BJ,Carpenter B,Ghorashian S,Wright GP,Flutter B,Xue SA,Chakraverty R,Morris EC (2012) Adoptive therapy with redirected MHC class I-restricted antigen-specific regulatory T cells is a potential novel cellular therapy for graft-versus-host disease BRITISH JOURNAL OF HAEMATOLOGY, 157, 8 - 8.
  13. Uttenthal BJ,Chua I,Morris EC,Stauss HJ (2012) Challenges in T cell receptor gene therapy. J Gene Med, 14(6), 386 - 399. 10.1002/jgm.2637.
  14. Ghorashian S,Holler A,Flutter B,Xue S-A,Fallah-Arani F,Sivakumaran J,Bennett C,Morris E,Stauss HJ,Chakraverty R (2012) CD4 help can overcome tolerance developing in adoptively-transferred T cells transduced with a self-specific TCR HUMAN GENE THERAPY, 23(5), A6 - A6.
  15. Field A-C,Stauss HJ,Morris EC,Qasim W (2012) Comparison on lentiviral and Sleeping Beauty transposon-mediated gene expression of T cell receptor genes HUMAN GENE THERAPY, 23(5), A10 - A11.
  16. Carpenter B,Ghorashian S,Nicholson E,Griffin J,Ahmadi M,Zhang L,Holler A,Stauss H,Morris E,Chakraverty R (2012) Targeting therapeutic T cells to tumour niches IMMUNOLOGY, 137, 53 - 54.
  17. Chua I,Ahmadi M,Xue S,Holler A,Zamoyska R,Stauss HJ,Morris EC (2012) Exploiting CD8 co-receptor to improve the function of genetically modified CD4 T cells for cancer immunotherapy IMMUNOLOGY, 137, 687 - 687.
  18. Thaventhiran JE,McGovern N,Dickinson R,Bigley V,Doffinger R,Kumararatne D,Chee R,Seneviratne S,Grimbacher B,Collin M,Morris E (2012) IDENTIFICATION OF GATA-2 MUTATIONS USING A SIMPLE SCREENING PROCEDURE IN PATIENTS WITH PAPILLOMA VIRUS INFECTIONS JOURNAL OF CLINICAL IMMUNOLOGY, 32, 83 - 83.
  19. Sive JI,Thomson KJ,Morris EC,Ward KN,Peggs KS (2012) Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clin Infect Dis, 55(10), 1362 - 1370. 10.1093/cid/cis689.
  20. Thomson K,Kayani I,Ardeshna KM,Morris E,Hough R,Goldstone AH,Linch DC,Peggs KS (2011) Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma BLOOD, 118(21), 158 - 158.
  21. Richardson S,Khan I,Rawstron A,Sudak J,Edwards N,Verfuerth S,Fielding A,Goldstone A,Kottaridis P,Morris E,Benjamin R,Peggs K,Thomson K,Vandenberghe E,Mackinnon S,Chakraverty R (2011) Risk-stratified adoptive cellular therapy following allogeneic haematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia British Jouurnal of Haematology, In press.
  22. Kothari J,Ljubic A,Peggs KS,Thomson K,Morris E,Virchis AE,Lambert J,Goldstone AH,Linch DC,Ardeshna KM (2011) Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure BLOOD, 118(21), 886 - 886.
  23. Peggs KS,Kayani I,Thomson K,Morris E,Kottaridis P,Ardeshna KM,Fielding A,Hough R,Goldstone AH,Chakraverty R,Linch DC,Mackinnon S (2011) Positive Pre-Transplantation ([18-F]) FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma BLOOD, 118(21), 881 - 881.
  24. Peggs KS,Kayani I,Edwards N,Kottaridis P,Goldstone AH,Linch DC,Hough R,Morris EC,Fielding A,Chakraverty R,Thomson KJ,Mackinnon S (2011) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol, 29(8), 971 - 978. 10.1200/JCO.2010.32.1711.
  25. Pospori C,Xue SA,Holler A,Voisine C,Perro M,King J,Fallah-Arani F,Flutter B,Chakraverty R,Stauss HJ,Morris EC (2011) Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination BLOOD, 117(25), 6813 - 6824. 10.1182/blood-2010-08-304568.
  26. Nicholson EK,Ahmadi M,Thomas S,Carpenter B,Voisine C,Xue S,Stauss HJ,Morris EC (2011) Improving the function of TCR gene modified T-cells for adoptive immunotherapy: co-transfer of additional CD3 molecules enhances functional avidity of TCR-transduced CD4+ T-cells BONE MARROW TRANSPLANTATION, 46, S323 - S323.
  27. Chua I,Holler A,Xue SHA,Zamoyska R,Stauss HJ,Morris EC (2011) T cells expressing genetically modified CDS co-receptor have enhanced T cell effector function HUM GENE THER, 22(10), A34 - A35.
  28. Uttenthal BJ,Carpenter B,Ghorashian S,Wright GP,Flutter B,Xue S,Chakraverty R,Morris EC (2011) Adoptive therapy with redirected MHC class I-restricted antigen-specific regulatory T cells is a potential novel cellular therapy for graft-versus-host disease.
  29. Xue SA,Gao L,Ahmadi M,Ghorashian S,Pospori C,Holler A,Thomas S,Morris E,Stauss HJ (2011) Generation of MHC-I restricted CD4+CMV and EBV specific T cells for the management of leukaemia patients HUM GENE THER, 22(10), A73 - A73.
  30. Nicholson E,Ahmadi M,Thomas S,Holler A,Carpenter B,Xue SA,Stauss H,Morris E (2011) Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells HUM GENE THER, 22(10), A119 - A119.
  31. Thomas S,Xue SA,Bangham CR,Jakobsen BK,Morris EC,Stauss HJ (2011) Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood, 118(2), 319 - 329. 10.1182/blood-2010-12-326736.
  32. Ahmadi M,King J,Xue S-A,Voisine C,Holler A,Wright G,Waxman J,Morris E,Stauss H (2011) CD3 limits the efficacy of TCR gene therapy in vivo IMMUNOLOGY, 135, 53 - 53.
  33. Ahmadi M,King JW,Xue SA,Voisine C,Holler A,Wright GP,Waxman J,Morris E,Stauss HJ (2011) CD3 limits the efficacy of TCR gene therapy in vivo. Blood, 118(13), 3528 - 3537. 10.1182/blood-2011-04-346338.
  34. Townsend W,Holroyd A,Pearce RM,Mackinnon S,Goldstone AH,Linch DC,Peggs KS,Thomson K,Singer M,Naik P,Howell D,Morris E (2011) A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically III Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning BLOOD, 118(21), 70 - 71.
  35. Cook G,Smith GM,Kirkland K,Lee J,Pearce R,Thomson K,Morris E,Orchard K,Rule S,Russell N,Craddock C,Marks DI,Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT) (2010) Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 16(10), 1419 - 1427. 10.1016/j.bbmt.2010.04.006.
  36. Pospori C,Xue SA,Holler A,Voisine C,Perro M,Fallah-Arani F,Flutter B,Chakraverty R,Stauss HJ,Morris EC (2010) Specificity for a tumor-associated self-antigen drives the development of functional memory T cells in the absence of vaccination HUMAN GENE THERAPY, 21(10), 1365 - 1366.
  37. Ahmadi M,King J,Nicholson E,Morris E,Stauss H (2010) Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules HUMAN GENE THERAPY, 21(10), 1414 - 1414.
  38. Chakraverty R,Orti G,Roughton M,Shen J,Fielding A,Kottaridis P,Milligan D,Collin M,Crawley C,Johnson P,Clark A,Parker A,Bloor A,Pettengell R,Snowden J,Pettitt A,Clark R,Hale G,Peggs K,Thomson K,Morris E,Mackinnon S (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 116(16), 3080 - 3088. 10.1182/blood-2010-05-286856.
  39. Mackinnon S,Lambert J,Bomanji J,Peggs K,Thomson K,Chakraverty R,Fielding A,Kottaridis P,Roughton M,Morris E,Goldstone A,Linch D,Ell P (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplant for lymphoma BONE MARROW TRANSPLANTATION, 45, S285 - S285.
  40. Richardson S,Vandenberghe E,Benjamin R,Sudak J,Goldstone A,Thomson K,Morris E,Peggs K,Fielding A,Kottaridis P,MacKinnon S,Chakraverty R (2010) Reduced-intensity allografting with in vivo T-cell depletion is associated with a favourable outcome in chronic lymphocytic leukaemia BONE MARROW TRANSPLANTATION, 45, S238 - S238.
  41. Thomson K,Morris E,Milligan D,Parker A,Hunter A,Cook G,Bloor A,Clark F,Kazmi M,Linch D,Chakraverty R,Peggs K,Mackinnon S (2010) T-cell depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma BONE MARROW TRANSPLANTATION, 45, S57 - S57.
  42. Peggs KS,Thomson K,Morris E,Kottaridis P,Hough R,Goldstone A,Fielding A,Ardeshna K,Chakraverty R,Linch DC,Mackinnon S (2010) Donor lymphocyte infusions guided by PET-CT offer durable salvage in relapsed Hodgkin's lymphoma post-allogeneic transplantation BONE MARROW TRANSPLANTATION, 45, S42 - S42.
  43. Mead A,Thomson KJ,Morris EC,Mohamedbhai S,Orti G,Chakraverty R,Linch DC,Mackinnon S,Peggs KS (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning BRITISH JOURNAL OF HAEMATOLOGY, 149, 21 - 21.
  44. Morris EC,Martinez-Davila I,Cellerai C,Chen F,Moss P,Khwaja A,Virchis A,Kottaridis P,Stauss HJ (2010) WT1 peptide vaccination in poor risk adult AML patients induces WT1-specific immune responses: Results of a leukaemia research supported phase I clinical trial, WTPV-001 BRITISH JOURNAL OF HAEMATOLOGY, 149, 16 - 16.
  45. Ahmadi M,King J,Nicholson E,Morris E,Stauss H (2010) Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules HUMAN GENE THERAPY, 21(4), 516 - 517.
  46. Perro M,Tsang J,Xue SA,Escors D,Cesco-Gaspere M,Pospori D,Gao L,Hart D,Collins M,Stauss H,Morris EC (2010) Lentiviral Vectors for TCR Gene Transfer: Improved Function of TCR-Transduced T Cells After Non-Activating Cytokine-Mediated Transduction HUMAN GENE THERAPY, 21(4), 512 - 512.
  47. Field AC,Stauss HJ,Goulden N,Morris E,Qasim W (2010) Defining an Optimal Promoter for Lentiviral Gene Expression of T Cell Receptor Genes HUMAN GENE THERAPY, 21(4), 509 - 510.
  48. Thomson KJ,Morris EC,Milligan D,Parker AN,Hunter AE,Cook G,Bloor AJ,Clark F,Kazmi M,Linch DC,Chakraverty R,Peggs KS,Mackinnon S (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol, 28(23), 3695 - 3700. 10.1200/JCO.2009.26.9100.
  49. Mead AJ,Thomson KJ,Morris EC,Mohamedbhai S,Denovan S,Orti G,Fielding AK,Kottaridis PD,Hough R,Chakraverty R,Linch DC,Mackinnon S,Peggs KS (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 115(25), 5147 - 5153. 10.1182/blood-2010-01-265413.
  50. Thomas S,Stauss HJ,Morris EC (2010) Molecular immunology lessons from therapeutic T-cell receptor gene transfer IMMUNOLOGY, 129(2), 170 - 177. 10.1111/j.1365-2567.2009.03227.x.

There are no biographical details to display

Keywords

  • Bone Marrow Transplantation
  • Phase I/II experimental medicine
  • TCR gene transfer
  • Tumour immunology